Bavarian Nordic Total Liabilities
Bavarian Nordic total liabilities. Based on the latest financial reports, Bavarian Nordic (BAVA) has total liabilities worth Dkr2.08 Billion DKK (≈ $326.13 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See BAVA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Total Liabilities of Bavarian Nordic (2000–2025)
Total liabilities of Bavarian Nordic from 2000 to 2025. This chart illustrates how Bavarian Nordic's total liabilities have evolved over time, based on quarterly financial data. Check asset resilience ratio of Bavarian Nordic to evaluate the company's liquid asset resilience ratio.
Bavarian Nordic Competitors by Total Liabilities
The table below lists competitors of Bavarian Nordic ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jilin Aodong Pharmaceutical Group Co Ltd
SHE:000623
|
China | CN¥3.55 Billion |
|
Relay Therapeutics Inc
NASDAQ:RLAY
|
USA | $57.43 Million |
|
First BanCorp
F:OLWN
|
Germany | €17.40 Billion |
|
ERMENEGILDO ZEG.DL -0001
F:JN0
|
Germany | €1.74 Billion |
|
China South Publishing & Media Group Co Ltd
SHG:601098
|
China | CN¥9.59 Billion |
|
Hypera S.A
SA:HYPE3
|
Brazil | R$14.46 Billion |
|
L&K Engineering Suzhou Co Ltd
SHG:603929
|
China | CN¥3.11 Billion |
|
TIZA Information Industry Corporation Inc
SHE:300209
|
China | CN¥2.53 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Bavarian Nordic's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Bavarian Nordic asset portfolio.
Liquidity & Leverage Metrics
Bavarian Nordic Total Liabilities Ratios Explained
Bavarian Nordic total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.22 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bavarian Nordic's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bavarian Nordic (2000–2025)
The table below shows the annual total liabilities of Bavarian Nordic from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Dkr2.08 Billion ≈ $326.13 Million |
-30.46% |
| 2024-12-31 | Dkr3.00 Billion ≈ $468.95 Million |
-25.32% |
| 2023-12-31 | Dkr4.01 Billion ≈ $627.91 Million |
-23.43% |
| 2022-12-31 | Dkr5.24 Billion ≈ $820.03 Million |
+11.17% |
| 2021-12-31 | Dkr4.71 Billion ≈ $737.63 Million |
+21.99% |
| 2020-12-31 | Dkr3.86 Billion ≈ $604.66 Million |
-25.41% |
| 2019-12-31 | Dkr5.18 Billion ≈ $810.70 Million |
+488.61% |
| 2018-12-31 | Dkr880.31 Million ≈ $137.73 Million |
+36.19% |
| 2017-12-31 | Dkr646.37 Million ≈ $101.13 Million |
-19.85% |
| 2016-12-31 | Dkr806.46 Million ≈ $126.18 Million |
+24.69% |
| 2015-12-31 | Dkr646.78 Million ≈ $101.19 Million |
+1.83% |
| 2014-12-31 | Dkr635.17 Million ≈ $99.38 Million |
+33.46% |
| 2013-12-31 | Dkr475.92 Million ≈ $74.46 Million |
-11.79% |
| 2012-12-31 | Dkr539.50 Million ≈ $84.41 Million |
-29.84% |
| 2011-12-31 | Dkr768.99 Million ≈ $120.31 Million |
+17.10% |
| 2010-12-31 | Dkr656.69 Million ≈ $102.74 Million |
+15.84% |
| 2009-12-31 | Dkr566.89 Million ≈ $88.69 Million |
-16.53% |
| 2008-12-31 | Dkr679.13 Million ≈ $106.26 Million |
+32.03% |
| 2007-12-31 | Dkr514.39 Million ≈ $80.48 Million |
+95.57% |
| 2006-12-31 | Dkr263.02 Million ≈ $41.15 Million |
-11.87% |
| 2005-12-31 | Dkr298.46 Million ≈ $46.70 Million |
+4.10% |
| 2004-12-31 | Dkr286.71 Million ≈ $44.86 Million |
+248.93% |
| 2003-12-31 | Dkr82.17 Million ≈ $12.86 Million |
-32.24% |
| 2002-12-31 | Dkr121.26 Million ≈ $18.97 Million |
+583.90% |
| 2001-12-31 | Dkr17.73 Million ≈ $2.77 Million |
-17.02% |
| 2000-12-31 | Dkr21.37 Million ≈ $3.34 Million |
-- |
About Bavarian Nordic
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an or… Read more